Doç. Dr. Murad Gulıyev

212eP Optimizing diagnostic approach and steroid use in GI toxicities associated with immune checkpoint inhibitors: A single center experience

Immuno-Oncology Technology, 2025

DOI 10.1016/j.iotech.2025.101295 Source: OpenAlex

Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim

Akademisyen Kitabevi eBooks, 2024

DOI 10.37609/akya.2380 Open-access full textSource: OpenAlex

Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

Journal of Oncological Sciences, 2024

DOI 10.37047/jos.2024-102164 1 citation (OpenAlex) Open-access full textSource: OpenAlex

Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

Journal of Chemotherapy, 2024

DOI 10.1080/1120009x.2024.2330835 PMID 38497444 7 citations (Europe PMC) Open-access full textSource: OpenAlex

Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients

Medicina, 2024

DOI 10.3390/medicina60121953 PMID 39768835 8 citations (Europe PMC) Open-access full textSource: OpenAlex

The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study

Breast Cancer Research and Treatment, 2024

DOI 10.1007/s10549-024-07291-0 PMID 38526689 6 citations (Europe PMC) Open-access full textSource: OpenAlex

Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

European Archives of Oto-Rhino-Laryngology, 2024

DOI 10.1007/s00405-024-08744-4 PMID 38795147 5 citations (Europe PMC) Open-access full textSource: OpenAlex

The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer

BMC Cancer, 2024

DOI 10.1186/s12885-024-13064-1 PMID 39448928 2 citations (Europe PMC) Open-access full textSource: OpenAlex

Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors

Clinical & Translational Oncology, 2024

DOI 10.1007/s12094-024-03696-x PMID 39225958 3 citations (Europe PMC) Source: OpenAlex

Could macrocytosis predict survival In advanced breast cancer patients that were treated with CDK 4–6 inhibitors?

The Breast, 2024

DOI 10.1016/j.breast.2024.103820 PMID 39405594 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer

Tumori Journal, 2024

DOI 10.1177/03008916241291989 PMID 39506383 Open-access full textSource: OpenAlex

68P Real-world clinical and treatment-related outcomes in specific subgroups of patients with BRAF-positive metastatic melanoma treated with dabrafenib-trametinib: Turkish Oncology Group study

ESMO Open, 2024

DOI 10.1016/j.esmoop.2024.102297 Source: OpenAlex

149P HER2-low status and response to neoadjuvant chemotherapy in early breast cancer

ESMO Open, 2023

DOI 10.1016/j.esmoop.2023.101488 Open-access full textSource: OpenAlex

Retrospective Analysis of Prognostic Factors and Survival in Multiple Myeloma Patients Aged 65 Years or Older at Diagnosis in a Real-Life Setting and a Proposed New Staging System

Blood, 2022

DOI 10.1182/blood-2022-170159 Source: OpenAlex

Real?world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple?negative breast ancer: A multicenter study by the Turkish Oncology Group

Source: acibadem.com.tr profile page

Real?world comparison of cabozantinib and sunitinib in advanced non?clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

Source: acibadem.com.tr profile page

Rethinking adjuvant chemotherapy in colon cancer patients aged ?65: Survival and prognostic factors

Source: acibadem.com.tr profile page

Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

Source: acibadem.com.tr profile page